Fmr LLC Raises Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

FMR LLC raised its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 0.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,824,675 shares of the company's stock after buying an additional 47,075 shares during the quarter. FMR LLC owned about 14.91% of Janux Therapeutics worth $355,475,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of JANX. Vanguard Group Inc. boosted its position in shares of Janux Therapeutics by 38.6% in the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company's stock worth $51,127,000 after purchasing an additional 378,477 shares in the last quarter. Logos Global Management LP boosted its holdings in Janux Therapeutics by 400.0% in the second quarter. Logos Global Management LP now owns 750,000 shares of the company's stock worth $31,418,000 after acquiring an additional 600,000 shares in the last quarter. Samlyn Capital LLC grew its stake in shares of Janux Therapeutics by 9.6% in the second quarter. Samlyn Capital LLC now owns 324,703 shares of the company's stock worth $13,602,000 after acquiring an additional 28,312 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Janux Therapeutics by 202.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company's stock valued at $10,639,000 after acquiring an additional 156,675 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Janux Therapeutics in the 2nd quarter worth about $5,715,000. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Price Performance

Shares of JANX traded down $1.18 during trading hours on Friday, hitting $45.21. The stock had a trading volume of 534,619 shares, compared to its average volume of 646,249. Janux Therapeutics, Inc. has a 12 month low of $7.79 and a 12 month high of $65.60. The stock has a fifty day moving average price of $49.81 and a 200 day moving average price of $45.78. The firm has a market capitalization of $2.37 billion, a PE ratio of -38.64 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business's quarterly revenue was down 82.6% on a year-over-year basis. As a group, analysts anticipate that Janux Therapeutics, Inc. will post -1.35 EPS for the current fiscal year.

Insider Buying and Selling at Janux Therapeutics

In other news, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the transaction, the chief executive officer now directly owns 282,054 shares of the company's stock, valued at $15,101,171.16. The trade was a 8.14 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the business's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $42.33, for a total value of $92,364.06. Following the transaction, the insider now owns 7,000 shares of the company's stock, valued at approximately $296,310. This trade represents a 23.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 445,610 shares of company stock valued at $20,578,666. Insiders own 29.40% of the company's stock.

Wall Street Analysts Forecast Growth

JANX has been the subject of a number of analyst reports. Stifel Nicolaus began coverage on shares of Janux Therapeutics in a research note on Friday, September 6th. They set a "buy" rating and a $70.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $63.00 price target on shares of Janux Therapeutics in a research report on Thursday, November 7th. Scotiabank lowered their price objective on Janux Therapeutics from $47.00 to $42.00 and set a "sector perform" rating on the stock in a research report on Friday, August 9th. Cantor Fitzgerald reiterated an "overweight" rating and set a $100.00 target price on shares of Janux Therapeutics in a research note on Thursday, November 7th. Finally, UBS Group assumed coverage on Janux Therapeutics in a research note on Thursday, October 24th. They issued a "buy" rating and a $69.00 price target for the company. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Janux Therapeutics currently has an average rating of "Buy" and a consensus target price of $67.70.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.